Carr Warner W, Yawn Barbara P
a Physician, Allergy & Asthma Associates of Southern California, A Medical Group , Southern California Research , Mission Viejo , CA , USA.
b Department of Family and Community Health , University of Minnesota , Minneapolis , MN , USA.
Postgrad Med. 2017 Aug;129(6):572-580. doi: 10.1080/00325481.2017.1333384. Epub 2017 Jun 9.
Allergic rhinitis (AR) may be regarded as a trivial issue unworthy of the doctor's time, and with the availability of many different over-the-counter (OTC) treatments, up to two thirds of patients self-manage AR before seeking medical care. Yet, AR can have a significant impact on health-related quality of life and is associated with a greater detriment to work productivity than other chronic diseases such as diabetes and hypertension. For many patients, the impact on quality of life is greater than suggested by reported symptoms and should also be a focus of treatment. Although many patients can effectively manage AR symptoms independently, a significant percentage will need direction from a physician to obtain optimal results. The availability of several different classes of treatment - including decongestants, sedating and non-sedating antihistamines, and more recently intranasal corticosteroids (INS) - has increased the complexity of self-management, leaving patients confused about the best approach to treatment. Treatment guidelines universally classify INS as the most effective medical agents available for use in the OTC and primary care settings. Many patients are unaware that INS are available OTC and that they are more effective than other therapies. Patients may have negative perceptions about the safety of INS and may have experienced unpleasant taste, scent, and feel with nasal sprays. Unless a patient volunteers the information, healthcare professionals (HCPs) may be unaware that the patient has significant AR and is using one or more OTC AR therapies. To address this gap in communication, HCPs must be proactive in identifying, assessing, and advising patients with AR, including best strategies to assess allergen trigger symptoms, which treatments are appropriate, and when and how to use them. Proper use of delivery devices is especially important. This article reviews the primary care management of AR in the context of the availability of effective OTC medicines.
变应性鼻炎(AR)可能被视为一个不值得医生花费时间的小问题,而且由于有许多不同的非处方(OTC)治疗方法可供选择,多达三分之二的患者在寻求医疗护理之前会自行管理AR。然而,AR会对健康相关生活质量产生重大影响,并且与工作效率的损害相比,比糖尿病和高血压等其他慢性病更大。对许多患者来说,对生活质量的影响比报告的症状所表明的更大,也应该是治疗的重点。虽然许多患者可以独立有效地管理AR症状,但很大一部分患者需要医生的指导才能获得最佳效果。几种不同类型的治疗方法的出现——包括减充血剂、镇静和非镇静抗组胺药,以及最近的鼻内皮质类固醇(INS)——增加了自我管理的复杂性,让患者对最佳治疗方法感到困惑。治疗指南普遍将INS列为可用于OTC和初级保健环境的最有效的药物。许多患者不知道INS有OTC剂型,也不知道它们比其他疗法更有效。患者可能对INS的安全性有负面看法,并且可能在使用鼻喷雾剂时经历过不愉快的味道、气味和感觉。除非患者主动提供信息,医疗保健专业人员(HCPs)可能不知道患者患有严重的AR并且正在使用一种或多种OTC AR疗法。为了弥补这种沟通差距,HCPs必须积极主动地识别、评估和为AR患者提供建议,包括评估过敏原触发症状的最佳策略、哪些治疗方法合适以及何时以及如何使用它们。正确使用给药装置尤为重要。本文在有有效OTC药物的背景下回顾了AR的初级保健管理。